Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within 6 months. Treatment options for these patients remain limited. Here we analyse 20 BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. Resistance mechanisms are identified in 9/11 progressing tumours and MAPK reactivation occurred in 9/10 tumours, commonly via BRAF amplification and mutations activating NRAS and MEK2. Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. Exome sequencing did not identify additional progression-specific resistance candidates. Nevertheless, most melanomas carried additional oncogenic mutations at baseline (for example, RAC1 and AKT3) that activate the MAPK and PI3K pathways and are thus predicted to diminish response to MAPK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In cell lines and xenografts, intrinsic and acquired resistance to signaling pathway inhibitors against estrogen, RAF, EGFR, PI3K, and others is sometimes associated with mutations in p16Ink4a, upregulated expression of cyclin D1 or other D-type cyclins, or upregulation of CDK4 or CDK6 (Jiang et al., 2016; Long et al., 2014; Yadav et al., 2014).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Long et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Cited by
Items 201–300 of 380
Ahmed, F., Tseng, H., Ahn, A., Gunatilake, D., Alavi, S., Eccles, M. R., Rizos, H., Gallagher, S. J., Tiffen, J. C., Hersey, P., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.09.030 · Cited by 18
Self-citationFlint, A. C., Mitchell, D. K., Angus, S. P., Smith, A. E., Bessler, W., Jiang, L., Mang, H. E., Li, X., Lu, Q., Rodriguez, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2854 · Cited by 18
Appenzeller, S., Gesierich, A., Thiem, A., Hufnagel, A., Jessen, C., Kneitz, H., Regensburger, M., Schmidt, C., Zirkenbach, V. A., Bischler, T., et al. (2018) · Cancer · doi:10.1002/cncr.31843 · Cited by 17
Do BRAF-targeted therapies have a role in the era of immunotherapy?
Braden, J., Conway, J. W., Wilmott, J. S., Scolyer, R. A., Long, G. V., & da Silva, I. P. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105314 · Cited by 18
Self-citationQu, J., Shen, Q., Li, Y., Kalyani, F. S., Liu, L., Zhou, J., & Zhou, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.911303 · Cited by 19
D’Andrea, M. A., & Reddy, G. K. (2019) · Radiation Oncology Journal · doi:10.3857/roj.2019.00437 · Cited by 17
“Multiple recent studies have demonstrated that resistance to molecularly targeted therapies is driven by multiple mechanisms functioning in concert, supporting these findings [26-28].”
BackgroundNovel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients
Rogiers, A., van den Oord, J. J., Garmyn, M., Stas, M., Kenis, C., Wildiers, H. P. M. W., Marine, J., & Wolter, P. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0304-7 · Cited by 17
Palrasu, M., Knapinska, A. M., Diez, J., Smith, L., Lavoi, T. M., Giulianotti, M. A., Houghten, R. A., Fields, G. B., & Minond, D. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000164 · Cited by 16
“There is a significant cross-talk between PI3K and MAPK pathways, and therefore the increased amount of PI3K-activated cells in response to MEK inhibition is not surprising and has been reported by others as a basis of acquired resistance to BRAFi/MEKi therapy [11–13 ,”
Ronco, C., Millet, A., Plaisant, M., Abbe, P., Hamouda‐Tekaya, N., Rocchi, S., & Benhida, R. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.054 · Cited by 15
The Role Of Circulating Tumor DNA In Therapeutic Resistance
Xu, C., Cao, H., Chen, S., & Feng, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s226202 · Cited by 17
“However, drug resistance may cause progression of disease within a year, which usually involves MAPK reactivation, commonly via BRAF amplification and mutations affecting NRAS or MEK2.(57) Gray et al analyzed the ctDNAs extracted from melanoma patients with progressive disease who initially responded to treatment with…”
BackgroundmiR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma
Nguyen, M.-H., Lin, C.-H., Liu, S., Miyashita, A., Ihn, H., Lin, H., Ng, C., Tsai, J.-C., Chen, M., Tsai, M.-S., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.10.009 · Cited by 18
Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
McKenna, S., & García-Gutiérrez, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105115 · Cited by 16
“RAC P29S/L Activating mutation + + + [61]”
Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma
Hanly, A. M., Gibson, F. T., Nocco, S. E., Rogers, S., Wu, M., & Alani, R. M. (2021) · JID Innovations · doi:10.1016/j.xjidi.2021.100090 · Cited by 19
“Combination epigenetic therapies for melanoma In BRAF-mutant melanomas, reactivation of the MAPK pathway is a crucial mechanism in the development of resistance to targeted therapies (Long et al., 2014), which is largely linked to changes in gene expression and transcriptional programs, as opposed to gene mutations (A…”
BackgroundHe, Y., Yang, Y., Xu, J., Liao, Y., Liu, L., Deng, L., & Xiong, X. (2020) · Journal of Cancer · doi:10.7150/jca.40974 · Cited by 14
Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02755-5 · Cited by 19
“in approximately half of the patients [9, 10].”
BackgroundFröhlich, L. M., Niessner, H., Sauer, B., Kämereit, S., Chatziioannou, E., Riel, S., Sinnberg, T. W., & Schittek, B. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0101 · Cited by 15
Arasi, M. B., Luca, G. D., Chronopoulou, L., Pedini, F., Petrucci, E., Flego, M., Stringaro, A., Colone, M., Pasquini, L., Spada, M., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.021 · Cited by 14
“13 Accumulating evidence suggests that non-coding RNAs (ncRNAs) play important roles in all key cellular processes.”
Dinter, L., Karitzky, P. C., Schulz, A., Wurm, A. A., Mehnert, M., Sergon, M., Tunger, A., Lesche, M., Wehner, R., Müller, A., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34807 · Cited by 16
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Scardaci, R., Berlinska, E., Scaparone, P., Michelina, S. V., Garbo, E., Novello, S., Santamaría, D., & Ambrogio, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13605 · Cited by 19
Paulitschke, V., Eichhoff, O. M., Cheng, P. F., Levesque, M. P., & Höeller, C. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000261 · Cited by 11
Making the right calls in precision oncology
Bungartz, K. D., Lalowski, K., & Elkin, S. K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4214 · Cited by 22
T cell receptor therapy against melanoma—Immunotherapy for the future?
Winge-Main, A., Wälchli, S., & Inderberg, E. M. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12927 · Cited by 15
“But despite initial impressive effect of BRAF- and MEK- inhibitors, resistance is acquired through recruitment of alternative signalling pathways (97).”
BackgroundLangdon, C. G., Held, M. A., Platt, J. T., Meeth, K. M., Iyidogan, P., Mamillapalli, R., Koo, A. B., Klein, M., Liu, Z. Z., Bosenberg, M., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12376 · Cited by 13
“28; 417–430 ORIGINAL ARTICLE Davies, 2014; Long et al., 2014; Wagle et al., 2014).”
Clark, M. E., Rizos, H., Pereira, M. R., McEvoy, A. C., Marsavela, G., Calapre, L., Meehan, K. L., Ruhen, O., Khattak, M. A., Meniawy, T. M., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27790 · Cited by 14
“BR4 expresses BRAF p55 (exon 4-10∆), SMU027 expresses BRAF p48 (exon 2-8∆) and WMD009 expresses BRAF p41 (exon 2-10∆) [9, 32].”
BackgroundSelf-citationWho’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma
Freiberger, S. N., Turko, P., Hüllner, M. W., Dummer, R., Morand, G. B., Levesque, M. P., Holzmann, D., & Rupp, N. J. (2021) · Cancers · doi:10.3390/cancers13112725 · Cited by 13
“As resistance mechanisms to targeted therapy with BRAF/MEK inhibitors, mutations in MAP2K1/2, alternative splice variants of BRAF, BRAF amplifications or a gain of NRAS mutations were detected [9,10].”
BackgroundNGS-Based Analysis of Atypical Deep Penetrating Nevi
Manca, A., Sini, M. C., Cesinaro, A. M., Portelli, F., Urso, C., Lentini, M., Cardia, R., Alós, L., Cook, M. G., Simi, S., et al. (2021) · Cancers · doi:10.3390/cancers13123066 · Cited by 13
“One of these, the C125S variant, was previously identified in melanoma patients who developed resistance to BRAF inhibitors [25,26].”
BackgroundOrgan Specific Copy Number Variations in Visceral Metastases of Human Melanoma
Papp, O., Doma, V., Gil, J., Marko‐Varga, G., Kárpáti, S., Tímár, J., & Vízkeleti, L. (2021) · Cancers · doi:10.3390/cancers13235984 · Cited by 14
Schulz, A., Raetz, J., Karitzky, P. C., Dinter, L., Tietze, J. K., Kolbe, I., Käubler, T., Renner, B., Beissert, S., Meier, F. E., et al. (2022) · Cancers · doi:10.3390/cancers14194930 · Cited by 18
The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma
Amaral, T. M. S., Nouri, N., & Garbe, C. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192469 · Cited by 15
“The intermittent dosing of BRAF inhibitors in combination with MEK inhibitors could be of clinical value since acquired resistance mechanisms to combination therapy are very similar to the acquired resistance mechanisms to BRAF inhibitors therapy alone [57].”
BackgroundEffect of stress-induced polyploidy on melanoma reprogramming and therapy resistance
Meierjohann, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.005 · Cited by 16
Wang, Y., Zhou, P., Qin, S., Xu, D., Liu, Y., Fu, W.-Y., Ruan, B.-B., Zhang, L., Zhang, Y., Wang, X., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00820 · Cited by 14
“Effect of 2-Pyridyl Cyclohexanone on Mitogen-Activated Protein Kinase (MAPK) Signaling in Eca109 and EC9706 Cells The MAPK signaling pathway (ERK, p38) is involved in the regulation of cell growth and differentiation, environmental adaptation to stress, and cancer progression (Long et al., 2014).”
BackgroundTargeted Therapy Innovations for Melanoma
Amarillo, D., Flaherty, K. T., & Sullivan, R. J. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.006 · Cited by 11
Krisp, C., Parker, R., Pascovici, D., Hayward, N. K., Wilmott, J. S., Thompson, J. F., Mann, G. J., Long, G. V., Scolyer, R. A., & Molloy, M. P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0227-2 · Cited by 11
Self-citationUpdates and challenges on treatment with BRAF/MEK-inhibitors in melanoma
Eroglu, Z., & Özgün, A. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1512402 · Cited by 14
“51 % w ith en co ra fe ni b vs .4 0% w ith ve m ur af en ib 66 % w ith co m bo vs .5 0% w ith en co ra fe ni b (p ar t 1 + 2) also demonstrating a plateau in long-term survival for patients treated with BRAF/MEK-inhibitors [16].”
BackgroundInfluentialMandalà, M., Palmieri, G., Ludovini, V., Baglivo, S., Marasciulo, F., Castiglione, F., Gili, A., Osella‐Abate, S., Rubatto, M., Senetta, R., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19281 · Cited by 11
Chen, J., Fang, C., Chang, C., Wang, K., Jin, H., Xu, T., Hu, J., Wu, W., Shen, E., & Zhang, K. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113710 · Cited by 15
Mezquita, L., Oulhen, M., Aberlenc, A., Deloger, M., Aldea, M. D., Honoré, A., Lécluse, Y., Howarth, K., Friboulet, L., Besse, B., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02535-0 · Cited by 14
“In melanoma, it has been proposed that the development of secondary resistance mechanisms can be due to (1) ERK reactivation through the MAPK pathway, (2) bypass signalling tracks leading to constitutive activation of alternative oncogenic pathways, (3) other unknown mechanisms [7 – 9].”
BackgroundPrecise Readout of MEK1 Proteoforms upon MAPK Pathway Modulation by Individual Ion Mass Spectrometry
Drown, B., Gupta, R., McGee, J. P., Hollas, M. A. R., Hergenrother, P. J., Kafader, J. O., & Kelleher, N. L. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c04758 · Cited by 12
Mastering the complexities of cancer nanomedicine with text mining, AI and automation
Shamay, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.057 · Cited by 14
Wan, Q., Jin, L., & Wang, Z. (2020) · Aging · doi:10.18632/aging.103974 · Cited by 11
“For instance, mutations of BRAF and NRAS target the mitogenactivated protein kinase (MAPK) pathway which is disorderly regulated in almost all melanomas [12, 13].”
BackgroundAya, F., Lanuza-Gracia, P., González-Pérez, A., Bonnal, S., Mancini, E., López-Bigas, N., Arance, A. M., & Valcárcel, J. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114048 · Cited by 14
Melanoma Single-Cell Biology in Experimental and Clinical Settings
Binder, H., Schmidt, M., Loeffler‐Wirth, H., Mortensen, L. S., & Kunz, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030506 · Cited by 11
“In an analysis of 10 patients under combined treatment with dabrafenib and trametinib, genetic resistance mechanisms were found in 9 out of 11 progressing tumors analyzed by a focused PCR panel for BRAF, NRAS, MEK1/2, and AKT1 [13].”
BackgroundInfluentialLim, S. Y., Lin, Y., Lee, J., Pedersen, B., Stewart, A., Scolyer, R. A., Long, G. V., Yang, J. Y. H., & Rizos, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105308 · Cited by 16
“Short-term ex vivo treatment of the tumour dissociates with DT effectively recapitulated early treatment-induced effects seen in patients, 12 with potent downregulation of ribosomal protein S6 signalling in melanoma cells indicative of MAPK activity suppression.”
Self-citationRole of exosomes in transforming growth factor-β-mediated cancer cell plasticity and drug resistance
Ruksha, T. G., & Palkina, N. V. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002322 · Cited by 16
Molecular Susceptibility and Treatment Challenges in Melanoma
Shenoy, P. V., Nag, R., Kolathur, K. K., Malik, Y., Varanasi, S. M., Angom, R. S., & Mukhopadhyay, D. (2024) · Cells · doi:10.3390/cells13161383 · Cited by 12
Melanoma: Pathogenesis and Targeted Therapy
Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 15
Schmitt, M., Sinnberg, T. W., Bratl, K., Zittlau, K. I., Garbe, C., Maček, B., & Nalpas, N. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100163 · Cited by 9
“(29), who analyzed ten malignant melanoma patients (supplemental Table S2.”
BackgroundCytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma
Barreno, A., & Orgaz, J. L. (2022) · Cells · doi:10.3390/cells11030518 · Cited by 9
Kakish, H. H., Ahmed, F. A., Elshami, M., Loftus, A. W., Hoehn, R. S., Ammori, J. B., Ocuin, L. M., Winter, J. M., Bordeaux, J. S., Mangla, A., et al. (2022) · Cancers · doi:10.3390/cancers14215184 · Cited by 10
“Additionally, two phase 3 trials (COMBI-d and COMBI-v) demonstrated improved effects f the combination of BRAF (da r fenib) and MEK (trametinib) inhibitors compared to monotherapy BRAF inhibition for adv ced melanoma [10,11].”
BackgroundFuture of combination therapy with dabrafenib and trametinib in metastatic melanoma
Zia, Y., Chen, L. R., & DAUD, A. I. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1085509 · Cited by 9
“Further, despite almost 70% response rate from combination therapy (combiDT) [9], BRAF mutant melanoma is known to develop a variety of clinical resistance mechanisms to targeted therapies including: BRAF amplification, MEK1/MEK2 mutations, and gain-of-function NRAS mutations [14].”
BackgroundCombined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia
Wander, S. A., Hasserjian, R. P., Oduro, K. A., Glomski, K., Nardi, V., Cote, G. M., Graubert, T. A., Brunner, A. M., Chen, Y.-B. A., & Fathi, A. T. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00032 · Cited by 10
Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?
Zeng, H., Liu, F., Zhou, H., & Zeng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.775100 · Cited by 10
Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
Wang, Z., Wu, R., Nie, Q., Bouchonville, K. J., Diasio, R. B., & Offer, S. M. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2020.12.003 · Cited by 10
“34, 35 Collectively, these results suggest that repression of CAF-1 may be an early event that promotes additional cellular and epigenetic changes that contribute to BRAFi resistance.”
BackgroundTakano, K., Munehira, Y., Hatanaka, M., Murakami, R., Shibata, Y., Shida, T., Takeuchi, K., Takechi, S., Tabata, T., Shimada, T., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0306 · Cited by 9
Representing mutations for predicting cancer drug response
Wall, P., & Ideker, T. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae209 · Cited by 8
“Other top mutated genes TP53 (Wang et al. 2023), PIK3CA (Candido et al. 2022), MAPK1 (Long et al. 2014), and more, are known modulators of BRAF activity and dabrafenib response, many of which are under clinical investigation for potential adjuvant targeting strategies in combination with BRAF/MEK…”
BackgroundLee, Y., & Park, D. (2021) · Anticancer Research · doi:10.21873/anticanres.14896 · Cited by 10
Hartung, N., Huynh, C. T.-K., Gaudy‐Marqueste, C., Flavian, A., Malissen, N., Richard, M. A., Hubert, F., & Grob, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176080 · Cited by 8
Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma
Kosnopfel, C., Sinnberg, T. W., Mane, S., Dongo, M., Garbe, C., & Niessner, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199794 · Cited by 9
“…such as trametinib (GSK1120212) or cobimetinib (GDC0973) could improve the duration of anti-tumor response and BRAFi/MEKi combinations are now standard of care following their FDA approval, therapeutic escape still occurs and frequently goes along with reactivation of the MAPK pathway [9–12].”
InfluentialOvercoming melanoma resistance to immune checkpoint blockade therapy using nano-strategies
Ding, Y., Liu, C., Wu, Y., & Fu, F. (2023) · Biomedical Technology · doi:10.1016/j.bmt.2023.03.003 · Cited by 7
Turner, E. L., Chen, L., Foulke, J. G., Gu, Z., & Tian, F. (2022) · Cancers · doi:10.3390/cancers14215449 · Cited by 10
Improving patient outcomes to targeted therapies in melanoma
Eroglu, Z., Smalley, K. S. M., & Sondak, V. K. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1178575 · Cited by 6
“Acquired resistance mechanisms to BRAF/MEK inhibitors are similar to mechanisms of resistance to BRAF inhibitors alone, such as BRAF amplifications and mutations activating NRAS and MEK2 [33].”
BackgroundVargas-Ibarra, D., Velez-Vasquez, M., & Bermudez‐Muñoz, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97061 · Cited by 10
Live-cell target engagement of allosteric MEKi on MEK–RAF/KSR–14-3-3 complexes
Marsiglia, W. M., Chow, A., Khan, Z. M., Liu, H., & Dar, A. C. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01454-8 · Cited by 9
“Although many excellent drugs have been developed against specific components of the pathway, such compounds often display limited efficacy or marked susceptibility to resistance 2,7–14 .”
Metzenmacher, M., Goetz, M., Herold, T., Stuschke, M., Aigner, C., Darwiche, K., Eberhardt, W., Schüler, M., & Wiesweg, M. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.008 · Cited by 6
Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance
Channathodiyil, P., May, K., Segonds-Pichon, A., Smith, P. D., Cook, S. J., & Houseley, J. M. (2022) · NAR Cancer · doi:10.1093/narcan/zcac032 · Cited by 6
“Individual cells enter the cell cycle even under acute MEK inhibition Inactivation of the ERK1/2 pathway by MEK inhibition induces G1 cell cycle arrest in BRAFV600E cell lines, including COLO205 (32,33).”
MethodInfluential3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells
Vital, P. D. S., Bonatelli, M., Dias, M. P., de Salis, L. V. V., Pinto, M. T., Baltazar, F., Maria–Engler, S. S., & Pinheiro, C. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415650 · Cited by 6
“Nevertheless, targeted therapy resistance patterns similar to those with monotherapy [16], low response rates, and slow onset found with immunotherapies [11–13] remain obstacles in melanoma treatment.”
BackgroundPatel, H. M., Mishra, R., Wier, A., Mokhtarpour, N., Merino, E. J., & Garrett, J. T. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001500 · Cited by 6
A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
Ruiz, E. M., Alhassan, S. A., Errami, Y., Elmageed, Z. Y. A., Fang, J. S., Wang, G., Brooks, M. A., Abi‐Rached, J., Kandil, E. H., & Zerfaoui, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098407 · Cited by 7
Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro
Yan, C., Zhao, L., Zhang, X., Chu, Z., Zhou, T., Zhang, Y., Geng, S., & Guo, K. (2023) · Journal of Biophotonics · doi:10.1002/jbio.202300356 · Cited by 8
Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas
Klotz, B. J., Kneitz, S., Lü, Y., Boswell, W. T., Postlethwait, J. H., Warren, W. C., Walter, R. B., & Schartl, M. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400051 · Cited by 7
Feng, T., Golji, J., Li, A., Zhang, X., Ruddy, D. A., Rakiec, D. P., Geyer, F. C., Gu, J., Gao, H., Williams, J. A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0028 · Cited by 7
Catoni, C., Poggiana, C., Facchinetti, A., Pigozzo, J., Piccin, L., Chiarion‐Sileni, V., Rosato, A., Minervini, G., & Scaini, M. C. (2022) · Cancers · doi:10.3390/cancers14174153 · Cited by 6
p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors
Maietta, I., Peschio, F. D., Buonocore, P., Viscusi, E., Laudati, S., Iannaci, G., Minopoli, M., Motti, M. L., & Falco, V. D. (2022) · Cancers · doi:10.3390/cancers15010121 · Cited by 7
“Initially, it was thought that the combination of BRAF and MEK inhibitors could be useful in evading resistance mechanisms, improving patients’ progression-free and overall survival; however, the use of this therapeutic combination proved to develop the same resistance mechanisms that are generated following the use o…”
BackgroundBrammeld, J. S., Petljak, M., Martincorena, I., Williams, S. P., García‐Alonso, L., Dalmases, A., Bellosillo, B., Robles‐Espinoza, C. D., Price, S., Barthorpe, S., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/066555 · Cited by 6
A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanomaPreprint
Marín-Béjar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Poźniak, J., Bervoets, G., Raemdonck, N. V., Pedri, D., Swings, T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.15.422929 · Cited by 6
Self-citationHaines, E., Burke, M., Catterall, R., de Jesus, V., Hidalgo, D., Li, B., Manna, J., Yang, A., Cavanaugh, J., Wessel, S. R., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01081-3 · Cited by 8
“While elevated pathway activation following chronic treatment of MAPK pathway inhibitors has been associated with resistance 22,23 , the expression of ERK1/2 target genes never rebounded above baseline levels upon IK-595 treatment.”
Zeng, P. Y., Meens, J., Karimi, A. H., Pan, H., Cecchini, M. J., Jarycki, L., Ryan, S. E. B., Dawson, A. E., Shaikh, M. H., Palma, D. A., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102820 · Cited by 5
Maik-Rachline, G., Cohen, I., & Seger, R. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_5 · Cited by 6
Diefenbach, R. J., Lee, J., Stewart, A., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Stretch, J. R., Long, G. V., Scolyer, R. A., & Rizos, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.820510 · Cited by 7
“Although, oncogenic BRAF and NRAS mutations are usually mutually exclusive (66), they co-occur in approximately 7% of untreated melanoma and NRAS mutations confer resistance in 27% of BRAF-mutant melanoma patients who progress on combination BRAF and MEK inhibitor therapy (67).”
BackgroundSelf-citationAlver, T. N., Heintz, K., Hovig, E. J., & Bøe, S. L. (2022) · Cancer Reports · doi:10.1002/cnr2.1736 · Cited by 6
“However, even though responses have improved when using combination treatments, resistance continues to be a major obstacle for efficient therapy responses.(6,7) In response to MAPK pathway inhibition, melanoma cells may”
BackgroundDosing of BRAF and MEK Inhibitors in Melanoma: No Point in Taking a Break
Lee, J., Carlino, M. S., & Rizos, H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.010 · Cited by 5
Self-citationLee, Y., Lee, S., Choi, D., Nam, H.-S., Kim, K. D., Choi, M., Cho, M.-K., & Lee, Y.-J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121006 · Cited by 4
“…immune checkpoint inhibitors targeting programmed death-1 (PD-1) or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) have improved outcomes for some patients, response rates vary widely, and treatment failure still occurs due to intrinsic non-responsiveness or acquired resistance [8–10].”
Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities
Chan, W. Y., da Silva, I. P., Long, G. V., & Rizos, H. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00199-6 · Cited by 6
Self-citationSong, J., Kobayashi, Y., Asano, Y., Sato, A., Taniguchi, H., & Ui‐Tei, K. (2022) · Cancers · doi:10.3390/cancers14133162 · Cited by 4
“In the case of BRAFV600E, which is the most frequent mutation in BRAF, it is reported that the MAPK or alternative escape pathway was reactivated during the treatment of BRAFV600E inhibitors [43,48,49].”
BackgroundEffects of FOXM1 inhibition and ionizing radiation on melanoma cells
Lee, V., McRobb, L. S., Moutrie, V., Santos, E., & Siu, T. L. T. (2018) · Oncology Letters · doi:10.3892/ol.2018.9482 · Cited by 5
“All cell lines were previously published except for WMD046 which is a short term patient derived sample sourced from Professor Rizos (12-16).”
Kakuda, Y., Kato, I., Kawata, T., Goto, K., Ito, K., Satake, R., Toki, S., Murata, H., Wasa, J., Katagiri, H., et al. (2024) · Pathology International · doi:10.1111/pin.13499 · Cited by 3
“16,17 This case had no history of BRAF/MEK inhibitor treatment.”
Weiss, L., Zhang, D., Kunz, W. G., Boeck, S. H., Curigliano, G., Subbiah, V., Lordick, F., Brummer, T., Westphalen, C. B., & Bielo, L. B. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100129 · Cited by 5
“75,76,79,80 In addition, BRAF monomer inhibitors themselves have been described to promote the process of RAF dimerization.”
Tumor heterogeneity, clonality and single cells
Kunz, M. (2016) · Experimental Dermatology · doi:10.1111/exd.13092 · Cited by 3
Discovery of SHR2415, a Novel Pyrrole-Fused Urea Scaffold ERK1/2 Inhibitor
Li, X., Dong, P., Zhang, T., Cai, G., Chen, Y., Dong, H., Yang, F., Zhang, L. J., Mao, Y., Feng, J., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00029 · Cited by 3
Pharmacological ascorbate induces sustained mitochondrial dysfunction
Carroll, R. S., Du, J., O’Leary, B. R., Steers, G. J., Goswami, P. C., Buettner, G. R., & Cullen, J. J. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.04.023 · Cited by 4
Tan, Y., Zhong, X., Wen, X., Yao, L., Shao, Z., Sun, W., Wu, J., Wen, G., Tang, D., Zhang, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698888 · Cited by 3
From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies
Long, G. V. (2015) · The Medical Journal of Australia · doi:10.5694/mja14.01718 · Cited by 3
Self-citationMing, Z., Lim, S. Y., Kefford, R. F., & Rizos, H. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12824 · Cited by 3
Self-citationIll, C. R., Marikar, N. C., Nguyen, V., Nangia, V., Darnell, A. M., Heiden, M. G. V., Reigan, P., & Spencer, S. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.19.629301 · Cited by 7
Dandou, S., Vendrell, J. A., Solassol, J., Louveau, B., Lebbé, C., Mourah, S., Rambow, F., Richard, E., du Manoir, S., Mangé, A., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-05291-3 · Cited by 3
The rise of new targets in melanoma
Bai, X. L., & Flaherty, K. T. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf251 · Cited by 2
Pandey, P., Verma, M., Siddiqui, S., Alkhathami, A. G., Saeed, M., Singh, M., & Khan, F. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03977-2 · Cited by 3
“It has been suggested that targeting MAPKs, such as ERK or JNK, could resolve this issue [71, 72].”
p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors
Maietta, I., Peschio, F. D., Buonocore, P., Viscusi, E., Laudati, S., Iannaci, G., Minopoli, M., Motti, M. L., & Falco, V. D. (2023) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr3ed.3.23.3 · Cited by 2
Schillo, J. L., Feddersen, C. R., Peplinski, R. M., Powell, L. S., Varzavand, A., Stipp, C. S., Riordan, J. D., & Dupuy, A. J. (2024) · NAR Cancer · doi:10.1093/narcan/zcad061 · Cited by 7
Lee, A. Q., Konishi, H., Ijiri, M., Li, Y., Panigrahi, A. R., CHIEN, J. R., & Satake, N. (2024) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2024.2343688 · Cited by 2
“This verifies trametinib’s mechanism of action–specifically, MEK inhibition–through downregulation of ERK phosphorylation 16–18”
Influential
Metadata
- Authors
- Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., Howle, J., Hayward, N. K., Johansson, P., Scolyer, R. A., Kefford, R. F., & Rizos, H.
- Affiliations
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Corresponding author
- Rizos, Helen
- ORCID
- Venue
- Nature Communications
- Published
- 2014-12-02
- Volume
- 5
- Issue
- 1
- Pages
- 5694-5694
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2003402062
- Cited by
- 375
- References
- 62
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 27 · 2023: 44 · 2022: 26 · 2021: 35 · 2020: 36 · 2019: 33 · 2018: 33 · 2017: 43 · 2016: 34 · 2015: 24 · 2014: 1
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Communications (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Westmead Millennium Institute for Medical Research
- Australian Cancer Research Foundation
- Cancer Institute NSW
- Melanoma Institute Australia
- Medical Research Council
- National Health and Medical Research Council (633004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dabrafenib, trametinib, combination therapy resistance, MAPK pathway reactivation, BRAF amplification, NRAS mutation, PI3K signaling, Rac1, AKT3, BRAF V600E mutation, resistance mechanisms
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Imidazoles, Melanoma, Membrane Proteins, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, GTP Phosphohydrolases, rac1 GTP-Binding Protein, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.